New agents in acute myeloid leukemia and other myeloid disorders

Cancer. 2004 Feb 1;100(3):441-54. doi: 10.1002/cncr.11935.

Abstract

Over the past several decades, improvements in chemotherapeutic agents and supportive care have resulted in significant progress in treating patients with acute myeloid leukemia (AML). More recently, advances in understanding the biology of AML have resulted in the identification of new therapeutic targets. The success of all-trans-retinoic acid in acute promyelocytic leukemia and of imatinib mesylate in chronic myeloid leukemia have demonstrated that targeted therapy may be more effective and less toxic when well defined targets are available. At the same time, understanding mechanisms of drug resistance and means to overcome them has led to modification of some of the existing cytotoxic agents. Rational design and conduct of clinical trials is necessary to ensure that the full potential of these new agents is realized.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Cyclosporine / therapeutic use
  • Cytosine / analogs & derivatives*
  • Cytosine / therapeutic use
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / therapeutic use
  • Dioxolanes / therapeutic use
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Immunotherapy / methods
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Severity of Illness Index
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Dioxolanes
  • Immunosuppressive Agents
  • Deoxycytidine
  • troxacitabine
  • Cyclosporine
  • Cytosine
  • gemcitabine